The War on Pharmaceutical Companies

In the United States, it is a dispute to earn high salary employment to cope with typical American expenditure. For some people, medical prescriptions are getting stronger to maintain health. When people discuss, health becomes a serious problem. Either way, at some point, everyone will be the victim of the pharmaceutical industry. The most important thing is that Americans pay a lot for prescriptions. Medical expenses in the US

MDMA was originally manufactured by German pharmaceutical company Merck in 1912. After World War I allies won, most of the German patents were ruined to the allies ruined. Patents explaining the chemical structure of MDMA were submitted somewhere and forgotten until the 1970s when American chemists named Alexander Surquin rediscovered it. Shulgin is an interesting character, I think it will become better known now. He studied organic chemistry at Harvard University at the age of 16, worked in the Navy during the Second World War, returned to Berkeley, California, and acquired a doctorate in biochemistry. He began working at Dow Chemical after school and made a new pesticide to make Dow several million dollars. Regardless of what he wants to do with the company, this gives Shulgin enough freedom.

Merck of the US pharmaceutical company became one of the top five pharmaceutical companies in the world in 2018. Merck is known as MSD outside North America. The company develops pharmaceuticals, vaccines and biologics in various fields such as cardiovascular, tumor, endocrine, infectious diseases and so on. Like Novartis, the company has only achieved a slight increase in revenue since 2016, but the ongoing success of Merck's best-selling drugs is driving sales. Januvia and Janument's total sales of diabetes medicines brought the company $ 1.522 billion beyond expectations.

Swiss pharmaceutical company Roche is the second largest pharmaceutical company in the world in 2018 and has 93,734 employees worldwide. The company has developed innovative drugs and devices for many important indications such as oncology, immunology, infectious diseases, neuroscience etc. The annual growth rate of the pharmaceutical division was 12.34%, the top 3 products accounted for 40% of Roche's total revenue in 2017 ($ 573.7 billion). Roche's best-selling medicine is also the world's three major anticancer drugs, Herceptin, Avastin and Rituximab. In 2018, we plan to submit six potential drugs in 2018, including Actemra for rheumatoid arthritis and systemic sclerosis, and tectonic tricks for various types of cancer.